The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy -- and those who won't. The latest trial results extend the test's reach.
The companies tout the deal as expanding Exact's commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The San Diego-based firm plans to integrate its "No Cell Left Behind" platform with electronic medical records and big data analytics.
Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round and a whopping 42 industry partnerships built around its novel liquid biopsy platform. For a team of just 70, the San Diego startup is doing pretty well.
Sometimes acquiring other drugmakers is the way to fill your company's development pipeline with new drugs. On Tuesday, Schering-Plough Corp. CEO Fred Hassan, a speaker at the Cleveland Clinic's ongoing Medical Innovation Summit, flew to Texas to launch Saphris, an anti-psychotic drug acquired in 2007.